Biotech News

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

Capricor Therapeutics (CAPR)Capricor Therapeutics2026-06-25 13:46 ESTClinical readout

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

Capricor Therapeutics

Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States